JUVÉDERM® VOLUMA™ XC IS FIRST AND ONLY PRODUCT OF ITS KIND APPROVED BY THE FDA FOR USE IN THE CHIN "Within my practice, I've seen a growing demand for patients looking to achieve more balanced ...

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...

Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...

Years ago, the beauty industry began focusing on properly proportioned facial features. First in trend was cheekbone definition, then the trend became lip-focused. While these areas have been the ...

Please provide your email address to receive an email when new articles are posted on . “Because there are no permanent adverse reactions or deforming reactions, I think the safety is assured,” Karen ...

(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...

Please provide your email address to receive an email when new articles are posted on . Juvéderm Voluma for facial revolumization produced results lasting up to a year in patients with little risk of ...

IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM ® Day on Wednesday, August 16, 2023. The celebration recognizes the ...

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...

Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and ...